Merus Reveals FDA Approval and Expedited Assessment of BLA for Zeno to Manage NRG1+ Lung and Pancreatic Cancer.

Positive Phase 2 Results for XyloCor Therapeutics’ Main Candidate XC001 Announced at SCAI 2024 and in the Journal Circulation: Cardiovascular Interventions.

Context Therapeutics has received FDA approval for its IND application, initiating a Phase 1 clinical trial of CTIM-76.

Remix Therapeutics has started dosing the first participants in a pair of Phase 1 studies. These trials are testing REM-422 in treating Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS).

Alpha-9 Oncology reports initial dosing of the first participant in a phase 1 trial for A9-3202, targeting locally advanced or metastatic melanoma patients.

Atsena Therapeutics Reveals Encouraging Results from Initial Group in Phase 1/2 Study of ATSN-201 Gene Treatment for X-linked Retinoschisis (XLRS).

EyeDNA Therapeutics Reveals Encouraging Two-Year Results at ARVO for its Phase 1/2 Study on HORA-PDE6b Genetic Treatment in Retinitis Pigmentosa Patients with Dual Mutations in PDE6b.

Adcentrx Therapeutics has received IND approval from China's NMPA for ADRX-0706, a new Nectin-4 antibody-drug conjugate designed to treat advanced solid tumors.

Modalis Therapeutics Announces Promising Results for MDL-101, a Novel Epigenome Editing Treatment for LAMA2 Congenital Muscular Dystrophy (LAMA2-CMD).

Inmagene Announces Encouraging Early Outcomes of Phase 2a Study on IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody, Prolonged Duration, Aimed at Treating Atopic Dermatitis.

Boehringer Ingelheim has revealed encouraging results from its HORNBILL Phase I/IIa trial for BI 764524.

BioAtla Receives FDA Approval to Begin Trials of BA3361, a Conditionally Active Biologic (CAB) Targeting Nectin-4 in Various Cancers.